Lorcaserin
- Generic Name
- Lorcaserin
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04572243
- Locations
- 🇺🇸
Children's of Alabama / University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸UCSD Rady's Children's Hosptial, San Diego, California, United States
Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT04457687
Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Chemotherapy-Induced Peripheral NeuropathyPrognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8
- Interventions
Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Southeastern Regional Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT03812523
- Locations
- 🇺🇸
Cancer Treatment Centers of America - Atlanta, Newnan, Georgia, United States
Lorcaserin for Cannabis Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 5
- Registration Number
- NCT03637842
- Locations
- 🇺🇸
Columbia Substance Treatment and Research Service, New York, New York, United States
Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Scripps Whittier Diabetes Institute
- Target Recruit Count
- 157
- Registration Number
- NCT03552107
- Locations
- 🇺🇸
Scripps Whittier Diabetes Institute, San Diego, California, United States
Rebalancing the Serotonergic System in Cocaine Dependence
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT03266939
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 15
- Registration Number
- NCT03253926
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Treatment With Lorcaserin for Cocaine Use: The TLC Study
- Conditions
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Glenn-Milo Santos
- Target Recruit Count
- 22
- Registration Number
- NCT03192995
- Locations
- 🇺🇸
San Francisco Department of Public Health, San Francisco, California, United States
Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 60
- Registration Number
- NCT03169816
- Locations
- 🇺🇸
Substance Treatment and Research Service (STARS), Columbia University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.